XNASTCRX
Market cap128mUSD
Jan 17, Last price
2.40USD
1D
-2.44%
1Q
-55.31%
IPO
-76.02%
Name
TScan Therapeutics Inc
Chart & Performance
P/E
—
P/S
6.09
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
21m
+55.52%
Net income
-89m
L+35.58%
CFO
-61m
L-7.74%
Profile
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 21,049 55.52% | 13,535 33.47% | |||
Cost of revenue | 202,660 | 85,308 | |||
Unusual Expense (Income) | |||||
NOPBT | (181,611) | (71,773) | |||
NOPBT Margin | |||||
Operating Taxes | (415) | ||||
Tax Rate | |||||
NOPAT | (181,611) | (71,358) | |||
Net income | (89,218) 35.58% | (65,806) 35.33% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 42,414 | 193 | |||
BB yield | -11.09% | -0.52% | |||
| Debt | |||||
Debt current | 9,839 | 3,681 | |||
Long-term debt | 148,226 | 138,997 | |||
Deferred revenue | 5,622 | ||||
Other long-term liabilities | 49 | ||||
Net debt | (33,979) | 17,614 | |||
| Cash flow | |||||
Cash from operating activities | (61,358) | (66,503) | |||
CAPEX | (3,146) | (4,225) | |||
Cash from investing activities | (60,759) | (4,225) | |||
Cash from financing activities | 135,443 | 29,356 | |||
FCF | (183,643) | (123,304) | |||
| Balance | |||||
Cash | 192,044 | 120,027 | |||
Long term investments | 5,037 | ||||
Excess cash | 190,992 | 124,387 | |||
Stockholders' equity | (247,592) | (158,376) | |||
Invested Capital | 499,760 | 343,843 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 65,600 | 24,048 | |||
Price | 5.83 276.13% | 1.55 -65.56% | |||
Market cap | 382,447 926.02% | 37,275 -65.35% | |||
EV | 348,468 | 54,889 | |||
EBITDA | (176,250) | (66,636) | |||
EV/EBITDA | |||||
Interest | 3,759 | 1,176 | |||
Interest/NOPBT | |||||